Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beatriz Perdiguero

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2015
NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responsesMauro Di Pilato, Ernesto Mejías-Pérez, Manuela Zonca, et al.
Journal of Virology|January 23, 2015
Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteinsJulie Delaloye, Abdelali Filali-Mouhim, Mark J Cameron, et al.
Vaccines|July 30, 2025
ISG15 as a Potent Immune Adjuvant in MVA-Based Vaccines Against Zika Virus and SARS-CoV-2Juan García-Arriaza, Michela Falqui, Patricia Pérez, et al.
Frontiers in Immunology|May 21, 2026
Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protectionLaura Marcos-Villar, Beatriz Perdiguero, Laura Sin, et al.
Frontiers in Immunology|July 5, 2023
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidateBeatriz Perdiguero, Laura Marcos-Villar, María López-Bravo, et al.
Plos One|August 1, 2012
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunityLaura Pattacini, Gregory J Mize, Jessica B Graham, et al.
Plos One|November 7, 2015
A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAARTCarmen Elena Gómez, Beatriz Perdiguero, Juan García-Arriaza, et al.
Frontiers in Immunology|January 11, 2020
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune ResponsesBeatriz Perdiguero, Carmen Elena Gómez, Juan García-Arriaza, et al.
Frontiers in Immunology|December 4, 2023
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env proteinBeatriz Perdiguero, Alexandra Hauser, Carmen Elena Gómez, et al.
Plos One|November 19, 2011
Improved NYVAC-based vaccine vectorsKaren V Kibler, Carmen E Gomez, Beatriz Perdiguero, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2015
NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responsesMauro Di Pilato, Ernesto Mejías-Pérez, Manuela Zonca, et al.
Journal of Virology|January 23, 2015
Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteinsJulie Delaloye, Abdelali Filali-Mouhim, Mark J Cameron, et al.
Vaccines|July 30, 2025
ISG15 as a Potent Immune Adjuvant in MVA-Based Vaccines Against Zika Virus and SARS-CoV-2Juan García-Arriaza, Michela Falqui, Patricia Pérez, et al.
Frontiers in Immunology|May 21, 2026
Preclinical evaluation of a multi-epitope mRNA vaccine platform for broad and durable SARS-CoV-2 protectionLaura Marcos-Villar, Beatriz Perdiguero, Laura Sin, et al.
Frontiers in Immunology|July 5, 2023
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidateBeatriz Perdiguero, Laura Marcos-Villar, María López-Bravo, et al.
Plos One|August 1, 2012
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunityLaura Pattacini, Gregory J Mize, Jessica B Graham, et al.
Plos One|November 7, 2015
A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAARTCarmen Elena Gómez, Beatriz Perdiguero, Juan García-Arriaza, et al.
Frontiers in Immunology|January 11, 2020
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune ResponsesBeatriz Perdiguero, Carmen Elena Gómez, Juan García-Arriaza, et al.
Frontiers in Immunology|December 4, 2023
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env proteinBeatriz Perdiguero, Alexandra Hauser, Carmen Elena Gómez, et al.
Plos One|November 19, 2011
Improved NYVAC-based vaccine vectorsKaren V Kibler, Carmen E Gomez, Beatriz Perdiguero, et al.
Pageof 7